Indeed, previous studies showed that patients with testicular germ cell tumors may benefit from doxorubicin treatment in clinical trials [44], and future clinical trials may be warranted to test doxorubicin in treating subgroups of patients with tumors expressing elevated SLC2A3. The gene discussed is SLC2A3; the disease is testicular germ cell tumor.